NewsBenzinga古根海姆维持对 Arcutis Biotherapeutics 的买入评级，将目标价上调至 44 美元 古根海姆维持对 Arcutis Biotherapeutics 的买入评级，将目标价上调至 44 美元 Benzinga 2026.10.19 16:33 (GMT+0) Open on Benzinga Other news Citigroup Maintains Buy on Fifth Third Bancorp, Raises Price Target to $63 Citigroup Maintains Buy on East West Bancorp, Raises Price Target to $155 Citigroup Maintains Neutral on BOK Financial, Lowers Price Target to $140 Citigroup Maintains Buy on Westinghouse Air Brake, Lowers Price Target to $334 Citigroup Maintains Neutral on Integra Lifesciences, Lowers Price Target to $14 Citigroup Maintains Buy on Pegasystems, Lowers Price Target to $50
